Yazaki T - Search Results

1

Inhibition of angiogenesis and growth of human non-malignant and malignant meningiomas by TNP-470.

Yazaki T, Takamiya Y, Costello PC, Mineta T, Menon AG, Rabkin SD, Martuza RL. Yazaki T, et al. J Neurooncol. 1995;23(1):23-9. doi: 10.1007/BF01058456. J Neurooncol. 1995. PMID: 7542695

2

Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas.

Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Mineta T, et al. Among authors: yazaki t. Nat Med. 1995 Sep;1(9):938-43. doi: 10.1038/nm0995-938. Nat Med. 1995. PMID: 7585221

3

Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1.

Yazaki T, Manz HJ, Rabkin SD, Martuza RL. Yazaki T, et al. Cancer Res. 1995 Nov 1;55(21):4752-6. Cancer Res. 1995. PMID: 7585498

4

Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide.

Yazaki T, Ahmad S, Chahlavi A, Zylber-Katz E, Dean NM, Rabkin SD, Martuza RL, Glazer RI. Yazaki T, et al. Mol Pharmacol. 1996 Aug;50(2):236-42. Mol Pharmacol. 1996. PMID: 8700129

5

Gene therapy: targeting tumor cells for destruction.

Rabkin SD, Mineta T, Miyatake S, Yazaki T. Rabkin SD, et al. Among authors: yazaki t. Hum Cell. 1996 Dec;9(4):265-76. Hum Cell. 1996. PMID: 9183657 Review.

6

Expression of L1 in primary astrocytes via a defective herpes simplex virus vector promotes neurite outgrowth and neural cell migration.

Yazaki T, Martuza RL, Rabkin SD. Yazaki T, et al. Brain Res Mol Brain Res. 1996 Dec 31;43(1-2):311-20. doi: 10.1016/s0169-328x(96)00186-6. Brain Res Mol Brain Res. 1996. PMID: 9037547 Free article.

7

Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates.

Hunter WD, Martuza RL, Feigenbaum F, Todo T, Mineta T, Yazaki T, Toda M, Newsome JT, Platenberg RC, Manz HJ, Rabkin SD. Hunter WD, et al. Among authors: yazaki t. J Virol. 1999 Aug;73(8):6319-26. doi: 10.1128/JVI.73.8.6319-6326.1999. J Virol. 1999. PMID: 10400723 Free PMC article.

8

Augmented therapeutic efficacy of an oncolytic herpes simplex virus type 1 mutant expressing ICP34.5 under the transcriptional control of musashi1 promoter in the treatment of malignant glioma.

Kanai R, Tomita H, Hirose Y, Ohba S, Goldman S, Okano H, Kawase T, Yazaki T. Kanai R, et al. Among authors: yazaki t. Hum Gene Ther. 2007 Jan;18(1):63-73. doi: 10.1089/hum.2006.107. Hum Gene Ther. 2007. PMID: 17238803

9

Enhanced therapeutic efficacy of oncolytic herpes vector G207 against human non-small cell lung cancer--expression of an RNA-binding protein, Musashi1, as a marker for the tailored gene therapy.

Kanai R, Eguchi K, Takahashi M, Goldman S, Okano H, Kawase T, Yazaki T. Kanai R, et al. Among authors: yazaki t. J Gene Med. 2006 Nov;8(11):1329-40. doi: 10.1002/jgm.965. J Gene Med. 2006. PMID: 16955534

10

Activation of human herpesvirus-6 in children with acute measles.

Suga S, Yoshikawa T, Asano Y, Nakashima T, Kobayashi I, Yazaki T. Suga S, et al. Among authors: yazaki t. J Med Virol. 1992 Dec;38(4):278-82. doi: 10.1002/jmv.1890380409. J Med Virol. 1992. PMID: 1335483

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

261 results

Search Page

Filters